Thursday - March 5, 2026
Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma
February 09, 2026
BOSTON, Massachusetts, Feb. 9 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

*

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

Dana-Farber Cancer Institute -led research helped drive an FDA label update for axicabtagene ciloleucel (Y . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products